Could chemo at home become a reality for myeloma patients?
NCT ID NCT05620238
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study explored whether multiple myeloma patients could safely administer the drug Carfilzomib at home instead of always going to the hospital. Nine patients who had already received at least one treatment cycle in the clinic were taught to give themselves the infusion on certain days. The goal was to see if this approach improved patient satisfaction and reduced time spent traveling and in the hospital.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Carfilzomib (Kyprolis)
What this could lead to
If successful, this approach could allow multiple myeloma patients to receive some chemotherapy infusions at home, cutting down hospital visits and freeing up time.
What could go wrong
This was a very small study (9 participants) looking only at satisfaction and time spent, not safety or effectiveness. Home infusion carries risks like infection or improper handling.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Odense University Hospital
Odense, 5000, Denmark